Skip to main content

Table 1 Severity of CAPS-related symptoms at baseline

From: Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

Symptom severity
n(%)
Physician global assessment
n= 35
Patient global assessment
n= 31
Physician assessment
    Skin rash
n= 35
Arthralgia
n= 35
Myalgia
n= 35
Headache/migraine
n= 35
Conjunctivitis
n= 35
Fatigue/migraine
n= 35
Absent 0 4 (12.9) 4 (11.4) 10 (28.6) 15 (42.9) 15 (42.9) 5 (14.3) 4 (11.4)
Minimal 2 (5.7) 6 (19.4) 6 (17.1) 5 (14.3) 4 (11.4) 2 (5.7) 8 (22.9) 2 (5.7)
Mild 7 (20.0) 8 (25.8) 9 (25.7) 10 (28.6) 8 (22.9) 9 (25.7) 11 (31.4) 7 (20.0)
Moderate 22 (62.9) 9 (29.0) 15 (42.9) 7 (20.0) 8 (22.9) 3 (8.6) 8 (22.9) 14 (40.0)
Severe 4 (11.4) 4 (12.9) 1 (2.9) 3 (8.6) 0 6 (17.1) 3 (8.6) 8 (22.9)